Saluda Medical announced that it appointed Barry Regan as its new president and CEO, effective July 14, 2025.
Regan most recently served as EVP, Global Operations at Dexcom and SVP, Global Operations at Wright Medical (acquired by Stryker).
“We are thrilled to welcome Barry to Saluda and are fortunate to augment our leadership team with his extensive experience at a critical juncture,” said Doug Godshall, Chairman of the Board of Directors of Saluda Medical. “Combined with the recent appointments of Mike Mathias as [CCO] and Jim Erickson as [CFO], we are confident Saluda has the right team of seasoned and driven leaders in place to fully realize our vision of bringing scientifically-based spinal cord stimulation, and neuromodulation more broadly, into the future with our unparalleled dose-controlled, closed-loop platform.”
More about new Saluda Medical CEO Barry Regan
Regan succeeds Jim Schuermann in the role. He brings 30 years of experience in medical devices and pharmaceuticals. At Dexcom, he oversaw the company’s capital investment strategy to support the scale-up of internal and external supplier manufacturing processes for its CGM technology.
In addition to his role at Wright, Regan served as SVP, Global Supply Chain at Smith+Nephew. He also served as VP, Manufacturing and GM, Puerto Rico, at AbbVie and spent 17 years at Abbott.
“I am thrilled to join Saluda as Chief Executive Officer at this exciting time,” said Regan. “I look forward to working with Mike Mathias, Jim Erickson, Doug, Bob, and the entire team to continue establishing Saluda as a new standard of care in neuromodulation and transforming the lives of patients with chronic neurological conditions.”
Minneapolis-based Saluda develops the Evoke neuromodulation system. The spinal cord stimulation (SCS) platform treats chronic pain. Saluda raised $100 million to support the technology earlier this year.
Related: Regan spoke to MassDevice in 2023 about Ireland’s impact on the medtech industry.)
